


ISSN: 2249-7137

Vol. 11, Issue 10, October 2021 Impact Factor: SJIF 2021 = 7.492



ACADEMICIA An International Multidisciplinary Research Journal



(Double Blind Refereed & Peer Reviewed Journal) DOI: 10.5958/2249-7137.2021.02212.6

A BRIEF REVIEW ON THE INDIAN HEALTH SYSTEM

Ms. Shiwangi*

*SBAS, Sanskriti University, Mathura, Uttar Pradesh, INDIA Email id: shiwangi.sobas@sanskriti.edu.in

ABSTRACT

In the world more than 200,000 leprosy cases are being registered in every passing year. But the situation has changed from the past few years. In 1982 when multi-drug therapy was introduced then the leprosy cases started reducing from the popularity rate of 57.8/10000 population in 1983 to 1/10000 population in the year 2005 i.e. 296,499. Wherein the popularity state of leprosy was 219,826 in the starting of 2006 and by the year 2018 the percentage rate of leprosy reduced to 0.67/10,000. Though India was highest saddle of leprosy, but with the World Health Organization instruction the National leprosy eradication programmer (NLEP) is interposing single-dose rifampicin for post-exposure prophylaxis in the entire high-autochthone localities of the nation. The main objective of this paper is to evaluate the cost-productiveness of single-dose rifampicin post-exposure prophylaxis in various leprosy ailment encumbrance circumstances. Wherein the cost-productiveness devolves on the measures by which the disability can be reduced. However, the medication is befitting cost-effective for the longer use, an everlasting perforation is being devoted.

Keywords: Leprosy, Single-dose rifampicin (SDR), Post-Exposure Prophylaxis (PEP), Costeffective.

REFERENCES

- 1. C. Jackson, "The General Health Questionnaire," *Occup. Med. (Chic. Ill).*, 2006, doi: 10.1093/occmed/kql169.
- 2. S. K. Noordeen, "The role of WHO including TDR,".
- **3.** H. S. Reforms, "Overview of the Health System in Ghana," *Kenya Serv. Provis. Assess. Surv.* 2004, 1999.

ACADEMICIA

ISSN: 2249-7137 Vol. 11, Issue 10, October 2021 Impact Factor: SJIF 2021 = 7.492

- 4. "New guidance on contact tracing.".
- **5.** A. Tiwari, L. Mieras, K. Dhakal, M. Arif, S. Dandel, and J. H. Richardus, "Introducing leprosy post-exposure prophylaxis into the health systems of India, Nepal and Indonesia: A case study," *BMC Health Serv. Res.*, 2017, doi: 10.1186/s12913-017-2611-7.
- 6. A. Tiwari, D. J. Blok, M. Arif, and J. H. Richardus, "Leprosy post-exposure prophylaxis in the indian health system: A cost-effectiveness analysis," *PLoS Negl. Trop. Dis.*, 2020, doi: 10.1371/journal.pntd.0008521.
- 7. Pn. Rao and S. Suneetha, "Current situation of leprosy in India and its future implications," *Indian Dermatol. Online J.*, 2018, doi: 10.4103/idoj.idoj_282_17.
- 8. World Health Organization, "Mental Health Action Plan 2013-2020," WHO Libr. Cat. DataLibrary Cat. Data, 2013.